Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Industries

Capital Raising and M&A in Life Sciences

Fasken

Life sciences deal activity and capital-raising strategies have steadily increased as the industry adapts to meet changing market and regulatory demands.

For emerging private companies, we help in the initial rounds of financing, including guidance through due diligence, refinement of governance and capital structure, preparation of subscription and offering materials, and negotiation of shareholder or other agreements to govern relationships going forward.

 

For later stage companies, we facilitate initial public offerings and reverse take-over listings (including through the TSX-Venture Exchange capital pool program), additional offerings (such as standby equity distribution agreements) and dual listings. We also prepare prospectuses and filing statements and organize the clearance of filings with securities regulators and stock exchange listing committees.

 

We advise life sciences clients in their acquisitions and divestments of businesses or products. Our M&A team manages complex transactions in the life sciences space, whether friendly or contested, and is supported by one of the leading life sciences regulatory teams in Canada.

 

As cross-border investments and transactions become more complex, we rely on a trusted network of advisors across 47 countries.

 

We advise clients involved in all aspects of a transaction, including acquirers, targets, boards and their special committees, lenders, financial advisors, investors and key shareholders. We also represent some of the leading investment banks in Canada and Europe operating in the life sciences space. 

 

Read our publications, browse some of our recent life sciences work we’ve assisted with or contact any of our lawyers to learn more.